Combination therapies in Myeloproliferative Neoplasms: Why do we need them and how to identify potential winners?

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 11, 2013, Pages 1410-1414

  Mclornan, Donal ^a   Harrison, Claire ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; TARGET OF RAPAMYCIN KINASE;

ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HEMATOLOGIC DISEASE; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; MYELOPROLIFERATIVE DISORDER; NOTE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MOLECULAR TARGETED THERAPY; MYELOPROLIFERATIVE DISORDERS; PHOSPHATIDYLINOSITOL 3-KINASES; TOR SERINE-THREONINE KINASES;

EID: 84891079273     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12202     Document Type: Note

References (36)

1. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013; 98: 1865-71.
2. Cervantes F, Kiladjian J-J, Niederwieser D, et al. Long-term safety, efficacy, and survival findings from comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). ASH Annual Meeting Abstracts. 2012; 120: Abstract 801.
3. Choong M, Pecquet C, Pendharkar V, et al. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. J Cell Mol Med. 2013; 17: 1397-409.
4. Bartalucci N, Tozzi L, Bogani C, et al. Co-targeting the PI3K/mTOR and JAK2 signaling pathways produces synergistic activity against myeloproliferative neoplasms. J Cell Mol Med. 2013; 17: 1385-96.
5. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006; 66: 11156-65.
6. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythaemia vera. Exp Hematol. 2004; 32: 179-87.
7. Shide K, Shimoda HK, Kumano T, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia. 2008; 22: 87-95.
8. Akada H, Yan D, Zou H, et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythaemia vera-like disease. Blood. 2010; 115: 3589-97.
9. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002; 296: 1655-7.
10. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7: 606-19.
11. Grimwade LF, Happerfield L, Tristram C, et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol. 2009; 147: 495-506.
12. Marty C, Lacout C, Droin N, et al. A role for reactive oxygen species in JAK2(V617F) myeloproliferative neoplasm progression. Leukemia. 2013; 27: 2187-95.
13. Xie X, Tang B, Zhou J, et al. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep. 2013; 30: 773-82. Doi: 10.3892/or.2013.2520.
14. Wang XJ, Feng CW, Li M. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem. 2013; 380: 57-66.
15. Burchert A, Wang Y, Cai D, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia. 2005; 19: 1774-82.
16. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995; 376: 599-602.
17. Kohn AD, Kovacina KS, Roth RA. Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase. EMBO J. 1995; 14: 4288-95.
18. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997; 7: 261-9.
19. Stokoe D, Stephens LR, Copeland T, et al. Dual role of phosphatidylinositol-3, 4, 5-trisphosphate in the activation of protein kinase B. Science. 1997; 277: 567-70.
20. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA. 2001; 98: 11598-603.
21. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96: 857-68.
22. Andjelkovic M, Alessi DR, Meier R, et al. J Biol Chem. 1997; 272: 31515-24.
23. Vannucchi AM, Bogani C, Bartalucci N, et al. The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms. Blood. 2009; 114: 2914A.
24. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002; 10: 457-68.
25. Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009; 21: 656-64.
26. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307: 1098-101.
27. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer. 2003; 3: 179-92.
28. Vinayak S, Carlson RW. mTOR inhibitors in the treatment of breast cancer. Oncology (Williston Park). 2013; 27: 38-44, 46, 48 passim. Review.
29. Park S, Chapuis N, Saint Marcoux F, et al., GOELAMS (Groupe Ouest Est d'Etude des Leucémies aiguës et Autres Maladies du Sang). A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia. 2013; 27: 1479-86.
30. Rizell M, Andersson M, Cahlin C, et al. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol. 2008; 13: 66-70.
31. Guglielmelli P, Barosi G, Rambaldi A, et al. AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011; 118: 2069-76. Doi:10.1182/blood-2011-01-330563.
32. Okabe S, Tauchi T, Tanaka Y, et al. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biol Ther. 2013; 15.
33. Chapuis N, Tamburini J, Green AS, et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res. 2010; 16: 5424-35.
34. Hurtado-Nedelec M, Csillag-Grange MJ, Boussetta T, et al. Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation. Haematologica. 2013; 98: 1517-24.
35. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythaemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013; 121: 4778-81.
36. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European LeukemiaNet (ELN) consensus report. Blood. 2013; 122: 1395-8.